{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:06:14Z","timestamp":1784019974991,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012323","name":"CSIR - Indian Institute of Chemical Biology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"ICMR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nano.2026.102990","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:22:02Z","timestamp":1783178522000},"page":"102990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dual PLGA nanoparticles co-encapsulating P5091 and Resveratrol synergistically target the USP7\u2013MDM2\u2013P53 axis for glioma therapy"],"prefix":"10.1016","volume":"75","author":[{"given":"Sunny","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-024-00516-y","article-title":"Glioma","volume":"10","author":"Weller","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the crossroads: current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.nano.2026.102990_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123018","article-title":"GBM immunotherapy: exploring molecular and clinical frontiers","volume":"356","author":"Ghosh","year":"2024","journal-title":"Life Sci"},{"issue":"50","key":"10.1016\/j.nano.2026.102990_bb0020","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000046442","article-title":"Comprehensive analysis of clinical, pathological, and molecular risk factors affecting the prognosis of patients with glioma","volume":"104","author":"Xu","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.nano.2026.102990_bb0025","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.chembiol.2024.08.010","article-title":"New therapies on the horizon: targeted protein degradation in neuroscience","volume":"31","author":"Gregory","year":"2024","journal-title":"Cell Chem Biol"},{"issue":"6","key":"10.1016\/j.nano.2026.102990_bb0030","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.chembiol.2024.04.002","article-title":"Molecular glues for protein-protein interactions: progressing toward a new dream","volume":"31","author":"Konstantinidou","year":"2024","journal-title":"Cell Chem Biol"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"10.1016\/j.nano.2026.102990_bb0040","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of immunotherapy resistance: lessons from glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0045","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1038\/s41467-019-11719-3","article-title":"Blood\u2013brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy","volume":"10","author":"Galstyan","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.nano.2026.102990_bb0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jconrel.2022.12.035","article-title":"Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy","volume":"354","author":"He","year":"2023","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12943-025-02284-z","article-title":"Regulation of cellular senescence in tumor progression and therapeutic targeting: mechanisms and pathways","volume":"24","author":"Liu","year":"2025","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12943-025-02419-2","article-title":"Cellular senescence in cancer: from mechanism paradoxes to precision therapeutics","volume":"24","author":"Feng","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.nano.2026.102990_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s11658-026-00907-x","article-title":"Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies","author":"Wu","year":"2026","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0070","article-title":"p53: from understanding its structure to advances in therapeutic targeting","volume":"11","author":"Wang","year":"2026","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.nano.2026.102990_bb0075","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","article-title":"Translating p53-based therapies for cancer into the clinic","volume":"24","author":"Peuget","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0080","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.nano.2026.102990_bb0085","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","article-title":"Understanding the complexity of p53 in a new era of tumor suppression","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0090","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s11658-025-00751-5","article-title":"Bypassing the guardian: regulated cell death pathways in p53-mutant cancers","volume":"30","author":"Chung","year":"2025","journal-title":"Cell Mol Biol Lett"},{"issue":"9\u201310","key":"10.1016\/j.nano.2026.102990_bb0095","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1101\/gad.347872.120","article-title":"The roles and regulation of MDM2 and MDMX: it is not just about p53","volume":"35","author":"Klein","year":"2021","journal-title":"Genes Dev"},{"issue":"8","key":"10.1016\/j.nano.2026.102990_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2024.119827","article-title":"E3 ubiquitin ligases and deubiquitinases in colorectal cancer: emerging molecular insights and therapeutic opportunities","volume":"1871","author":"Kumar","year":"2024","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"8","key":"10.1016\/j.nano.2026.102990_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2025.120049","article-title":"CHIP modulates Wnt\/\u03b2-catenin signalling in colorectal cancer through proteasomal degradation of DDX17","volume":"1872","author":"Kumar","year":"2025","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11033-026-11579-3","article-title":"Murine double minute 2 (MDM2) as an appealing target for natural products in cancer treatment","volume":"53","author":"Singh","year":"2026","journal-title":"Mol Biol Rep"},{"issue":"2","key":"10.1016\/j.nano.2026.102990_bb0115","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.drudis.2020.10.028","article-title":"The emerging nature of ubiquitin-specific protease 7 (USP7): a new target in cancer therapy","volume":"26","author":"Nininahazwe","year":"2021","journal-title":"Drug Discov Today"},{"issue":"11","key":"10.1016\/j.nano.2026.102990_bb0120","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/14728222.2023.2266571","article-title":"Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment","volume":"27","author":"Carreira","year":"2023","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"10.1016\/j.nano.2026.102990_bb0125","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13117","article-title":"Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity","volume":"19","author":"He","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.nano.2026.102990_bb0130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fcell.2020.00233","article-title":"Targeting USP7-mediated deubiquitination of MDM2\/MDMX-p53 pathway for cancer therapy: are we there yet?","volume":"8","author":"Qi","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0135","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12943-024-02005-y","article-title":"Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options","volume":"23","author":"Gao","year":"2024","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1016\/j.nano.2026.102990_bb0140","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.chembiol.2024.05.003","article-title":"Mitochondrial RelA empowers mtDNA G-quadruplex formation for hypoxia adaptation in cancer cells","volume":"31","author":"Tang","year":"2024","journal-title":"Cell Chem Biol"},{"issue":"9","key":"10.1016\/j.nano.2026.102990_bb0145","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.chembiol.2024.08.007","article-title":"Membrane remodeling via ubiquitin-mediated pathways","volume":"31","author":"Jacomin","year":"2024","journal-title":"Cell Chem Biol"},{"issue":"47","key":"10.1016\/j.nano.2026.102990_bb0150","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1038\/s41388-022-02486-5","article-title":"USP7 targets XIAP for cancer progression: establishment of a p53-independent therapeutic avenue for glioma","volume":"41","author":"Saha","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0155","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1038\/s41598-020-62292-5","article-title":"Resveratrol and its related polyphenols contribute to the maintenance of genome stability","volume":"10","author":"Matsuno","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.nano.2026.102990_bb0160","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41556-024-01592-8","article-title":"MDM2 functions as a timer reporting the length of mitosis","volume":"27","author":"Fulcher","year":"2025","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/s11658-021-00293-6","article-title":"Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?","volume":"26","author":"Haronikova","year":"2021","journal-title":"Cell Mol Biol Lett"},{"issue":"2","key":"10.1016\/j.nano.2026.102990_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/biom15020240","article-title":"Ubiquitin-specific protease inhibitors for cancer therapy: recent advances and future prospects","volume":"15","author":"Bakkar","year":"2025","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0175","doi-asserted-by":"crossref","DOI":"10.1186\/s41120-022-00060-7","article-title":"PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives","volume":"8","author":"Alvi","year":"2022","journal-title":"AAPS Open"},{"key":"10.1016\/j.nano.2026.102990_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124697","article-title":"Glioma nanotherapy: unleashing the synergy of dual-loaded DIM and TMZ","volume":"665","author":"Sarkar","year":"2024","journal-title":"Int J Pharm"},{"issue":"13","key":"10.1016\/j.nano.2026.102990_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201605094","article-title":"Biocompatible D\u2013A semiconducting polymer nanoparticle with light-harvesting unit for highly effective photoacoustic imaging guided photothermal therapy","volume":"27","author":"Zhang","year":"2017","journal-title":"Adv Funct Mater"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep"},{"issue":"18","key":"10.1016\/j.nano.2026.102990_bb0195","doi-asserted-by":"crossref","first-page":"19153","DOI":"10.1021\/acs.jmedchem.5c01229","article-title":"Isoquinolinone\u2013naphthoquinone hybrids as potent PARP-1 inhibitors induce apoptosis in glioma via DNA damage and ROS generation","volume":"68","author":"Pathi","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.nano.2026.102990_bb0200","first-page":"1","article-title":"Phytochemical profiling of Andrographis beddomei C.B. Clarke using UHPLC-ORBITRAP-MS\/MS approach and assessment of cytotoxicity in cisplatin-resistant ovarian cancer","author":"Kumar","year":"2025","journal-title":"Nat Prod Res"},{"issue":"4","key":"10.1016\/j.nano.2026.102990_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2025.195120","article-title":"Identification of a novel p65-p68 loop: a crucial determinant for p68 gene regulation in oncogenesis","volume":"1868","author":"Ghosh","year":"2025","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"39","key":"10.1016\/j.nano.2026.102990_bb0210","doi-asserted-by":"crossref","first-page":"65339","DOI":"10.18632\/oncotarget.18689","article-title":"Anti-SSTR2 peptide based targeted delivery of potent PLGA encapsulated 3, 3\u2032-diindolylmethane nanoparticles through blood brain barrier prevents glioma progression","volume":"8","author":"Bhowmik","year":"2017","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.nano.2026.102990_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176225","article-title":"Spheroids as a type of three-dimensional cell cultures\u2014examples of methods of preparation and the most important application","volume":"21","author":"Bia\u0142kowska","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.nano.2026.102990_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00044-025-03492-4","article-title":"The evolution of Nutlins as p53-MDM2 inhibitors","volume":"35","author":"Bazanov","year":"2026","journal-title":"Med Chem Res"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426000912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426000912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:25:54Z","timestamp":1784017554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963426000912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"alternative-id":["S1549963426000912"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2026.102990","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual PLGA nanoparticles co-encapsulating P5091 and Resveratrol synergistically target the USP7\u2013MDM2\u2013P53 axis for glioma therapy","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2026.102990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102990"}}